We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit PR Newswire ROCKVILLE, Md., April 24, 2024 ROCKVILLE, Md., April 24, 2024 /PRNewswire/...
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire ROCKVILLE, Md., March 28, 2024 A single ABBV-RGX-314 gene...
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md., March 27, 2024 ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc...
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., March 11, 2024 ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced...
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 0.312304809494 | 16.01 | 16.66 | 15.18 | 478795 | 15.86681188 | CS |
4 | -5.02 | -23.8140417457 | 21.08 | 21.57 | 15.18 | 463603 | 18.05578915 | CS |
12 | 3.61 | 28.9959839357 | 12.45 | 28.8 | 11.83 | 756608 | 19.70672872 | CS |
26 | 0.47 | 3.01475304682 | 15.59 | 28.8 | 11.83 | 652779 | 18.34950445 | CS |
52 | -2.78 | -14.7558386412 | 18.84 | 28.8 | 11.83 | 514721 | 18.33914824 | CS |
156 | -18.17 | -53.0820917324 | 34.23 | 46.46 | 11.83 | 433810 | 24.61586727 | CS |
260 | -36.65 | -69.5313982167 | 52.71 | 55.23 | 11.83 | 443956 | 30.84064324 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions